According to a story from outsourcing-pharma.com, the US Food and Drug Administration (FDA) has recently started a new initiative with the opening of its Compounding
Orphazyme, a biopharmaceutical company, has recently released the data from their study of arimoclomol. This product is meant for the treatment of Niemann-Pick disease
Herantis Pharma has been conducting a study of their treatment for Parkinson’s disease, which is cerebral dopamine neurotrophic factor (CDNF). Phase 1/2 has been
According to an article in BioSpace, the FDA recently approved the PARP inhibitor Lynparza that was developed by Merck and AstraZeneca to be used
According to a story from Medgadget, a team of scientists from Columbia University have been working on a robotic device that could assist patients with
January is Cervical Health Awareness Month! The New Year holiday is all about taking stock of one’s self and making efforts to improve or set
© Copyright Patient Worthy
